Viewing nowPregabalin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
SaeHan Pharmaceutical Co., Ltd.

MFDS item code 201109158 · Approved 2011.10.25 · Insurance code 651300470
Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures (regardless of whether they are secondary generalized). Finally, it helps alleviate the symptoms of fibromyalgia. It is effective in improving symptoms of various nerve-related disorders.
This drug is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys as unchanged drug. Since the clearance of this drug is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* *: For women, multiply the result obtained from the above calculation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the method of administration. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because data on safety and efficacy are insufficient. Adolescent patients aged 12 ~17 years: Administration is not recommended because data on safety and efficacy are insufficient.
This medication may increase the risk of suicidal thoughts or behaviors, so mood or behavioral changes should be closely monitored during treatment. Patients with allergies to the components of this medication should not take it. Diabetic patients may need to adjust the dosage of blood glucose control medications due to weight gain. If symptoms of angioedema appear, treatment should be discontinued immediately, and elderly patients should be cautious of falls due to dizziness or drowsiness. Vision changes such as blurred vision may occur, so consult a doctor if unusual symptoms arise. When discontinuing this medication, withdrawal symptoms such as insomnia, headache, and anxiety may occur, so medical advice should be sought. Due to the risk of substance abuse, extra caution is needed for those with a history of substance abuse, and signs of misuse should be monitored during treatment. Patients with reduced kidney function may need dosage adjustments. Patients with heart disease should exercise caution when taking this medication. As it has central nervous system depressant effects, caution should be taken when using it with opioid pain relievers due to an increased risk of respiratory depression. In early pregnancy, there is a risk of fetal malformation, so pregnant women should either avoid taking it or make careful decisions, and women of childbearing potential should use effective contraception. Lactating women should consider discontinuing breastfeeding or the medication, as this drug may pass into breast milk. It is advisable to avoid dangerous activities such as driving or operating machinery until dizziness or drowsiness completely resolves. In case of overdose, confusion, drowsiness, and seizures may occur, and immediate medical attention is required; blood dialysis treatment may be needed if necessary. This medication should be kept out of reach of children and should not be transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture, and it is recommended to keep it at room temperature between 15 to 30 degrees Celsius. This way, the efficacy of the medication can be safely maintained.
Hard capsules with brownish-red upper and white lower parts containing white or grayish-white crystalline powder
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
SaeHan Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.